BioCentury | Mar 10, 2014
Finance

Innovator capital rationing

...cancer $89 Series B, C Abingworth Management, Brookside Capital, Deerfield Capital, Domain Associates, Omega Funds, Oxford Bioscience Partners...
BioCentury | Aug 5, 2013
Finance

Deciphering Dicerna's future

...Capital and Deerfield Capital - as well as Omega Funds. Existing investors Abingworth, Domain Associates, Oxford Bioscience Partners...
BioCentury | Aug 5, 2013
Financial News

Dicerna completes venture financing

...million Investors: RA Capital Management; Brookside Capital; Omega Funds; Deerfield Capital; Abingworth Management; Domain Associates; Oxford Bioscience Partners...
BioCentury | Aug 2, 2013
Top Story

Dicerna raises $60 million in series C

...Capital; Deerfield Capital; and Omega Funds also participated, along with existing investors Abingworth; Domain Associates; Oxford Bioscience Partners...
BioCentury | Apr 23, 2012
Finance

Venture Tracks

...with an emphasis on oncology, neurology and infectious disease. Baron was a general partner at Oxford Bioscience Partners...
BioCentury | Mar 5, 2012
Finance

Putting debt to work

...was with Korea Seoul Life Sciences Fund (KSLSF), whose GPs are Hanwha Venture Capital and Oxford Bioscience Partners...
BioCentury | Feb 13, 2012
Finance

Radius comes full circle

...stake); The Wellcome Trust (13.4%); HealthCare Ventures (10.7%); BB Biotech Ventures (8.9%); Saints Capital (8.9%); Oxford Bioscience Partners...
BioCentury | Dec 5, 2011
Finance

IPO for Rib-X

...research grants and tax credits. Investors include Warburg Pincus (45.9% pre-IPO stake); Saints Capital (23.1%); Oxford Bioscience Partners...
BioCentury | May 23, 2011
Finance

Saints marches in

...investment firm Saints Capital did a deal last week with early stage life sciences VC Oxford Bioscience Partners...
...The move will help free Oxford Bioscience to focus more on investing two new funds: Oxford Bioscience Partners...
BioCentury | Apr 18, 2011
Strategy

Supercharging Astex

...undisclosed targets in multiple disease areas. The company's VCs - Apax Partners , Abingworth Bioventures, Oxford Bioscience Partners...
Items per page:
1 - 10 of 193
BioCentury | Mar 10, 2014
Finance

Innovator capital rationing

...cancer $89 Series B, C Abingworth Management, Brookside Capital, Deerfield Capital, Domain Associates, Omega Funds, Oxford Bioscience Partners...
BioCentury | Aug 5, 2013
Finance

Deciphering Dicerna's future

...Capital and Deerfield Capital - as well as Omega Funds. Existing investors Abingworth, Domain Associates, Oxford Bioscience Partners...
BioCentury | Aug 5, 2013
Financial News

Dicerna completes venture financing

...million Investors: RA Capital Management; Brookside Capital; Omega Funds; Deerfield Capital; Abingworth Management; Domain Associates; Oxford Bioscience Partners...
BioCentury | Aug 2, 2013
Top Story

Dicerna raises $60 million in series C

...Capital; Deerfield Capital; and Omega Funds also participated, along with existing investors Abingworth; Domain Associates; Oxford Bioscience Partners...
BioCentury | Apr 23, 2012
Finance

Venture Tracks

...with an emphasis on oncology, neurology and infectious disease. Baron was a general partner at Oxford Bioscience Partners...
BioCentury | Mar 5, 2012
Finance

Putting debt to work

...was with Korea Seoul Life Sciences Fund (KSLSF), whose GPs are Hanwha Venture Capital and Oxford Bioscience Partners...
BioCentury | Feb 13, 2012
Finance

Radius comes full circle

...stake); The Wellcome Trust (13.4%); HealthCare Ventures (10.7%); BB Biotech Ventures (8.9%); Saints Capital (8.9%); Oxford Bioscience Partners...
BioCentury | Dec 5, 2011
Finance

IPO for Rib-X

...research grants and tax credits. Investors include Warburg Pincus (45.9% pre-IPO stake); Saints Capital (23.1%); Oxford Bioscience Partners...
BioCentury | May 23, 2011
Finance

Saints marches in

...investment firm Saints Capital did a deal last week with early stage life sciences VC Oxford Bioscience Partners...
...The move will help free Oxford Bioscience to focus more on investing two new funds: Oxford Bioscience Partners...
BioCentury | Apr 18, 2011
Strategy

Supercharging Astex

...undisclosed targets in multiple disease areas. The company's VCs - Apax Partners , Abingworth Bioventures, Oxford Bioscience Partners...
Items per page:
1 - 10 of 193